No Prescription |
 |
 | ||
|
TEGRETOL Carbatrol |
|
| ||
No Prescription » Prescription Drugs 15 » TEGRETOL Carbatrol Carbamazepine is used alone or in combination with other medications to treat certain types of seizures in patients with epilepsy. It is also used to treat trigeminal neuralgia (a condition that causes facial nerve pain). Carbamazepine extended-release capsules (Equetro brand only) are used to treat episodes of mania (frenzied abnormally excited or irritated mood) or mixed episodes (symptoms of mania and depression that happen at the same time) in patients with bipolar I disorder (manic-depressive disorder; a disease that causes episodes of depression episodes of mania and other abnormal moods).Carbamazepine is in a class of medications called anticonvulsants. It works by reducing abnormal excitement in the brain. Buy TEGRETOL Carbatrol and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About TEGRETOL Carbatrol: Product Type: Prescription Drugs 15 TEGRETOL ( Carbatrol Equetrol Atretol Depitol Epitol Generic Carbamazepine ) TEGRETOL (Carbatrol Equetrol Atretol Depitol Epitol Generic Carbamazepine) Carbatrol Equetrol Atretol Depitol Epitol Generic Carbamazepine 100mg Tabs Carbatrol Equetrol Atretol Depitol Epitol Generic Carbamazepine TEGRETOL
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
